Open an account

iSpecimen

ISPC · NASDAQ

$0.9599+$0.0498 (+5.47%)TodayMarket closed ·
Prev close $0.9101

About ISPC

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. The company is headquartered in Woburn, Massachusetts and currently employs 7 full-time employees. The company went IPO on 2021-06-17. The firm addresses a critical challenge, which focuses on connecting life science researchers who need human biofluids, tissues, and living cells (biospecimens) for their research. The Company’s iSpecimen Marketplace platform is designed to solve this problem and transform the biospecimen procurement process to accelerate medical discovery. Its technology consolidates the biospecimen buying experience in a single, online marketplace that brings together healthcare providers who have biospecimens and researchers across industry, academia, and government institutions who need them. In addition to providing the technology platform to connect researchers and healthcare providers, the Company handles all marketing, sales, contracting, and compliance functions across both sides of the marketplace. The iSpecimen Marketplace technology comprises four functional areas: search, workflow, data and administrative, compliance and reporting.

Employees
24
Headquarters
Woburn, Massachusetts
Listed
Jun 17, 2021
Sector
Health Care
Industry
Health Care Technology
Website
ispecimen.com

ISPC key statistics

Market cap
2.42M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
367.99K
Volume
155.02K
Open price
$0.94
High today
$0.9949
Low today
$0.8901
52 Week high
$36.32
52 Week low
$0.90

iSpecimen (ISPC) at a glance

iSpecimen (ISPC) last traded at $0.9599, with a market cap of 2.42M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.8901 and $0.9949. The current price is 7.8% above the day's low and 3.5% below its high.

Volume so far is 155.02K shares, below the average of 367.99K shares a day.

Over the past year iSpecimen has ranged from $0.90 to $36.32, and now sits 0% of the way up that range.

iSpecimen met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q3 FY24 it reported -$2.10 per share against an estimate of -$0.1938.

ISPC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 30.9% on average.

  1. Q4 FY22: reported -$192.00 per share against an estimate of -$306.00
  2. Q1 FY23: reported -$216.00 per share against an estimate of -$261.12
  3. Q2 FY23: reported -$312.00 per share against an estimate of -$244.80
  4. Q3 FY23: reported -$184.00 per share against an estimate of -$285.60
  5. Q4 FY23: reported -$256.00 per share against an estimate of -$195.84
  6. Q1 FY24: reported -$256.00 per share against an estimate of -$220.32
  7. Q2 FY24: reported -$152.00 per share against an estimate of -$228.48
  8. Q3 FY24: reported -$2.10 per share against an estimate of -$0.1938

ISPC news

  • Rishabh Mishra

    Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)

  • Avi Kapoor

    Dow Jumps 350 Points; BJ's Wholesale Club Posts Upbeat Earnings

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • Avi Kapoor

    Dow Jumps Over 600 Points; Netflix Shares Tumble After Q1 Results

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • Avi Kapoor

    Dow Gains Over 300 Points; US GDP Growth Revised Lower In Q4

Similar companies

Companies in the same industry as iSpecimen

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.